Benevira

We are committed to advancing our pipeline of first-in-class antivirals with additional discovery efforts to follow. We believe that the next frontier of unmet medical need in virology exists among the acute and subacute viral infections. Our team employs state-of-the-art drug discovery modalities to identify novel, first-in-class antivirals.

For example, our vision is that an Evrys Bio product will address hepatitis caused by hepatitis B virus and hepatitis C virus. Our vision is to develop safe, first-in-class antivirals that address the problem of acquired drug-resistance and provide unique broad-spectrum treatment options. Current products only address one or the other, not both. Innovation Evrys Bio was founded on breakthrough discoveries from Princeton University. Because Evrys Bio products address the infectious disease condition, as opposed to targeting a specific virus-type, the practice of medicine will be transformed. These highly-innovative products are early-stage, yet we are making great progress in solving real clinical challenges and unmet medical need.

Vir’s core capabilities include our deep immunology and virology expertise, our proven world-class monoclonal antibody platform with AI-led protein engineering capabilities, as well as our T cell-based viral vector platform. Vir has built a broad pipeline with several ongoing trials – including two late-stage programs in chronic hepatitis delta and chronic hepatitis B – that we believe will support near- and long-term growth, along with multiple potential INDs in the next 12-24 months. If you share our goal of addressing the unmet needs of patients around the world, please visit our careers page for open positions. Our growth and pursuit of scientific innovation is fueled by our leading monoclonal antibody (mAb) platform that has a proven track record and is further strengthened by our artificial intelligence-led mAb optimization and engineering capabilities. Our ability to develop impactful medicines for major public health challenges is a testament to the company’s deep knowledge of immunology and our ability to understand the interplay between viruses and the human immune system.”. We have an industry-leading management team and Board of Directors with significant immunology and infectious diseases experience, including a proven track record of progressing product candidates from early-stage research through clinical development, and worldwide regulatory approval and commercialization. We offer the opportunity to do challenging, rewarding work as part of our world class teams in the U.S.

We pioneered a new product category of Viral Sensitizers (VSE™) that removes the barriers to manufacturing effective viral medicines at scale. Customized VSE formulations optimize research processes and enhance production. Virica was founded in 2018 based on a decade of research in the laboratory of Dr. Recent influenza outbreaks and the COVID-19 pandemic highlight the need for scalability in the production of vaccines. Virica has the products and experience to combat these challenges. Here is a snapshot of organizations with whom we share knowledge by attending meetings or giving presentations. Virica is a member of BIOTECanada, an association building a climate for biotechnology firms to succeed in today’s hyper-competitive economy. Virica is a member of Alliance of Regenerative Medicine.

This strategy extends the proven benefits of testing for viruses such as the flu or COVID-19, which have both caused suffering and death among vulnerable people but can be treated if properly diagnosed. While Altesa initially is investigating the impact of Vapendavir on those with COPD, we believe this medication hold strong promise to help other vulnerable people who can experience fatal consequences from common viral infections, including chronically ill children, adults with cancer, or those with diseases that impair the immune system, such as transplant recipients or people with HIV.

We are an innovative science-led orthomolecular healthcare company focused on developing safe and effective virus agnostic treatment models that will revolutionise the way we protect ourselves against the Coronavirus. COVIMRO™ is a Biotech research company specialising in agnostic antiviral solutions. Covimro has a virus agnostic, 3 stage design architecture that addresses the full lifecycle of the virus. Covimro 1 has Virucidal MOA via the chemistry of lipid polymorhphism. Covimro 3 has Anti proliferative MOA by targeting and inhibiting viral enzyme 3CL. The Covimro architecture has the potential to be commercialised into candidate product pipelines across 3 industries; Consumer, OTC, and Pharmaceuticals. We are developing study plans together with our university partnerships and the private sector to further extend our scientific lead. Covid-19 is the most serious public health crisis facing the world today.